Amedisys Inc
Find Ratings ReportsAMEDISYS INC's gross profit margin for the fourth quarter of its fiscal year 2023 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. AMEDISYS INC has weak liquidity. Currently, the Quick Ratio is 0.99 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 1.42% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q4 FY23 | Q4 FY22 |
---|---|---|
Net Sales ($mil) | 570.79 | 562.06 |
EBITDA ($mil) | 52.53 | 56.81 |
EBIT ($mil) | 48.39 | 51.58 |
Net Income ($mil) | 19.32 | 31.72 |
Balance Sheet | Q4 FY23 | Q4 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 138.86 | 54.13 |
Total Assets ($mil) | 2060.17 | 1976.25 |
Total Debt ($mil) | 487.21 | 537.94 |
Equity ($mil) | 1066.51 | 1051.57 |
Profitability | Q4 FY23 | Q4 FY22 |
---|---|---|
Gross Profit Margin | 43.72 | 43.85 |
EBITDA Margin | 9.2 | 10.1 |
Operating Margin | 8.48 | 9.18 |
Sales Turnover | 1.09 | 1.13 |
Return on Assets | -0.47 | 6.0 |
Return on Equity | -0.91 | 11.28 |
Debt | Q4 FY23 | Q4 FY22 |
---|---|---|
Current Ratio | 1.05 | 1.09 |
Debt/Capital | 0.31 | 0.34 |
Interest Expense | 8.23 | 5.78 |
Interest Coverage | 5.88 | 8.92 |
Share Data | Q4 FY23 | Q4 FY22 |
---|---|---|
Shares outstanding (mil) | 32.67 | 32.52 |
Div / share | 0.0 | 0.0 |
EPS | 0.59 | 0.97 |
Book value / share | 32.65 | 32.34 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 287319.0 | 352397.0 |
HOLD. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Conducting a second comparison, its price-to-book ratio of 2.84 indicates a significant discount versus the S&P 500 average of 4.68 and a discount versus the subsector average of 3.19. The current price-to-sales ratio is well below the S&P 500 average, but above the subsector average. The valuation analysis reveals that, AMEDISYS INC seems to be trading at a premium to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AMED NM | Peers 21.06 | AMED 22.09 | Peers 54.00 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. AMED's P/E is negative making this valuation measure meaningless. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. AMED is trading at a significant discount to its peers. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
AMED 19.01 | Peers 15.17 | AMED NA | Peers 0.67 | |||||||||||||||||||||
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. AMED is trading at a significant premium to its peers. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
AMED 2.84 | Peers 3.19 | AMED -108.51 | Peers 33.66 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. AMED is trading at a discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, AMED is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
AMED 1.36 | Peers 1.25 | AMED 0.17 | Peers 10.95 | |||||||||||||||||||||
Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. AMED is trading at a valuation on par with its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. AMED significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||